About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Philadelphia | 20,904 Studies Near You | Clareo Health

Clinical Trials LocationsPhiladelphia

Clinical Trials in Philadelphia

Discover 20,904 clinical trials near Philadelphia, Pennsylvania. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 15461-15480 of 20,904 trials

TERMINATEDPhase 2< 1 mile

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

NCT01774851

To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone

HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction Cancer+1 more

Merrimack Pharmaceuticals84 participantsStarted Jan 2013

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +18 more locations

COMPLETEDPhase 4< 1 mile

Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface

NCT00782171

The purpose of this study is to evaluate the performance of a new dental implant with a modified surface in different loading protocols.

Partial Edentulism

Institut Straumann AG266 participantsStarted Jul 2004

Boca Raton, Florida, United States • Indianapolis, Indiana, United States • Philadelphia, Pennsylvania, United States +16 more locations

Find Trials by Condition in Philadelphia

Breast Cancerin Philadelphia Lung Cancerin Philadelphia Prostate Cancerin Philadelphia Colorectal Cancerin Philadelphia Melanomain Philadelphia Leukemiain Philadelphia Lymphomain Philadelphia Pancreatic Cancerin Philadelphia Ovarian Cancerin Philadelphia Brain Cancerin Philadelphia

Data from ClinicalTrials.govTerms

COMPLETEDPhase 117 miles

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

NCT01277692

This study is a three Part, Phase 1, randomized, dose-escalation, fusion, placebo-controlled, double-blind study to determine the safety, tolerability and Pharmacokinetic (PK) profile of GSK2336805 in healthy subjects and the safety, tolerability, PK, and antiviral profile of GSK2336805 in subjects chronically infected with HCV: i. Single doses in healthy subjects and the effect of food on GSK2336805 PK (Part 1). ii. Repeat doses in healthy subjects (Part 2) iii. Single doses in chronically infected HCV positive subjects (Part 3).

GlaxoSmithKline58 participantsStarted Nov 2010

Chula Vista, California, United States • Lenexa, Kansas, United States • Willingboro, New Jersey, United States

COMPLETED25 miles

Emotional Experiences in Fathers of NICU Infants

NCT00306605

This study is designed to evaluate the emotional experiences of fathers who have preterm infants who are hospitalized in a (neonatal intensive care unit)NICU setting. In addition, we will compare the emotional responses experienced by father of surgical NICU babies and fathers of medical NICU babies. Our primary hypothesis is that paternal stress levels will be lower for those fathers of infants who are hospitalized in a medical NICU compared with fathers of infants who are hospitalized in a surgical NICU. Secondary hypotheses include: 1) Stress levels for fathers of hospitalized infants will decrease over time; 2) Depressive symptomatology modulates perceived stress in fathers of NICU infants.

StressDepressive Symptomatology

Christiana Care Health Services35 participantsStarted Mar 2006

Newark, Delaware, United States • Wilmington, Delaware, United States

COMPLETEDPhase 233 miles

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

NCT00856492

RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also may stop the growth of tumor cells by blocking blood flow to the tumor. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which treatment regimen is more effective in treating women with breast cancer. PURPOSE: This randomized phase II trial is studying paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, cyclophosphamide, and pegfilgrastim to compare how well they work when given with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer.

SWOG Cancer Research Network215 participantsStarted Apr 2010

Mobile, Alabama, United States • Little Rock, Arkansas, United States • Berkeley, California, United States +363 more locations

COMPLETED36 miles

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

NCT01414595

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies tissue samples from patients with non-small cell lung cancer.

Alliance for Clinical Trials in Oncology248 participantsStarted Mar 2012

Los Angeles, California, United States • Lewes, Delaware, United States • Newark, Delaware, United States +8 more locations

COMPLETEDNA36 miles

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

NCT00417040

This pilot clinical trial studies how well using the internet to collect symptoms and the ability to carry out daily activities works in patients with enrolled on Cancer and Leukemia Group B (CALGB) studies. A study that evaluates a patient's ability to use a clinic waiting room computer to report their symptoms and their ability to carry out daily activities may help doctors understand a patient's use of a computer to report symptoms.

Prostate CancerBreast CancerLung Cancer+3 more

Alliance for Clinical Trials in Oncology325 participantsStarted Dec 2006

Castro Valley, California, United States • Castro Valley, California, United States • Fremont, California, United States +92 more locations

COMPLETEDPhase 136 miles

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT02107235

The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus negative positive (HPV (+)) Head and Neck Squamous Cell Carcinoma. This study will determine the highest safe dose of oral rigosertib that can be used with cisplatin and CRT. This study will also record any side effects that may occur and measure tumor sizes and how long patients live.

Head and Neck NeoplasmsCarcinoma, Squamous Cell

Traws Pharma, Inc.2 participantsStarted Jan 2014

Aurora, Colorado, United States • Newark, Delaware, United States • The Bronx, New York, United States +1 more locations

COMPLETEDPhase 2/348 miles

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

NCT01061736

Primary Objectives: Part A (dose ranging study): To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks. Part B (pivotal study): To demonstrate that sarilumab added to MTX was effective in: * reduction of signs and symptoms of rheumatoid arthritis at 24 weeks * inhibition of progression of structural damage at 52 weeks * improvement in physical function at 16 weeks Secondary Objectives: Part B: To demonstrate that sarilumab added to MTX was effective in induction of a major clinical response at 52 weeks To assess the safety of sarilumab added to MTX To document the pharmacokinetic profile of sarilumab added to MTX in participants with active rheumatoid arthritis who were inadequate responders to MTX therapy.

Rheumatoid Arthritis

Sanofi1,675 participantsStarted Mar 2010

Anniston, Alabama, United States • Birmingham, Alabama, United States • Gilbert, Arizona, United States +259 more locations

COMPLETEDPhase 348 miles

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

NCT01768572

Primary Objective: To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.

Rheumatoid Arthritis

Sanofi202 participantsStarted Mar 2013

Huntsville, Alabama, United States • Colorado Springs, Colorado, United States • Aventura, Florida, United States +75 more locations

COMPLETEDPhase 348 miles

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

NCT02057250

Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants. Secondary Objective: To compare the pharmacokinetic (PK) exposure of sarilumab administered by AID versus prefilled syringes (PFS).

Sanofi217 participantsStarted Mar 2014

Huntsville, Alabama, United States • Peoria, Arizona, United States • Roseville, California, United States +50 more locations

COMPLETEDPhase 281 miles

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

NCT01584531

The primary objectives of this study are to determine if rigosertib sodium, given orally in the form of soft gel capsules, is safe and is associated with a reduction in the number of blood transfusion units that are needed in patients with myelodysplastic syndrome (MDS) classified as Low or Intermediate-1 (Int-1) (any cytogenetics) or trisomy 8 Intermediate 2 (Int-2) in the International Prognostic Scoring System (IPSS) who are transfusion-dependent. Rigosertib will be taken on days 1 to 21 of a 21-day cycle.

Myelodysplastic SyndromeMDSTrisomy 8

Traws Pharma, Inc.82 participantsStarted May 2012

Scottsdale, Arizona, United States • Atlanta, Georgia, United States • Rochester, Minnesota, United States +2 more locations

COMPLETEDPhase 181 miles

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

NCT01048619

In other clinical studies, ON 01910.Na has been safely given intravenously to Patients with advanced cancers. However, to treat some Patients, it may be better if ON 01910.Na could be given by mouth. This study will determine if it is safe to give ON 01910.Na by mouth, what is the highest dose can be safely given by mouth, and how much of the drug gets from the stomach into the blood stream when it is given by mouth.

Myelodysplastic Syndrome

Traws Pharma, Inc.36 participantsStarted Dec 2009

Tampa, Florida, United States • New York, New York, United States

COMPLETED81 miles

BioFiber Scaffold Post-Market Observational Study

NCT01849458

The aim of this study is to collect and report data from a consecutive series of patients implanted with these products as part of a post-market surveillance plan for CE Mark approval in the European Union.

Full Thickness Rotator Cuff Tear

Stryker Trauma and Extremities50 participantsStarted Mar 2013

New York, New York, United States • Charlottesville, Virginia, United States • Saint-Grégoire, France

COMPLETEDPhase 1103 miles

Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients

NCT00573560

The CardioKinetix Ventricular Partitioning Device (VPD) is intended to isolate the malfunctioning portion of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. By isolating the malfunctioning portion of the left ventricle, it is hypothesized that the left ventricle will pump more effectively.

CardioKinetix, Inc20 participantsStarted Dec 2007

Washington D.C., District of Columbia, United States • Chicago, Illinois, United States • Asheville, North Carolina, United States +4 more locations

COMPLETEDPhase 3176 miles

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

NCT02121210

Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: * To evaluate the other safety aspects of sarilumab administered as monotherapy. * To assess the exposure of sarilumab administered as monotherapy.

Rheumatoid Arthritis

Sanofi132 participantsStarted Jun 2014

Gilbert, Arizona, United States • Upland, California, United States • South Miami, Florida, United States +25 more locations

COMPLETEDPhase 2197 miles

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431

Primary Objective: To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis (NIU). Secondary Objectives: To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of subcutaneous sarilumab in participants with NIU. To evaluate the change in macular edema. To evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal vessel leakage. To evaluate the effect of sarilumab on reducing concomitant immunosuppressant therapy. To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the pharmacokinetics of sarilumab in NIU participants. To evaluate the immunogenicity with anti-drug antibodies (ADA).

Sanofi58 participantsStarted Oct 2013

Worcester, Massachusetts, United States • Omaha, Nebraska, United States • Slingerlands, New York, United States +17 more locations

COMPLETEDPhase 2257 miles

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

NCT00607997

This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML

LeukemiaAcute DiseaseAcute Myeloid Leukemia+2 more

Sunesis Pharmaceuticals113 participantsStarted May 2008

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • La Jolla, California, United States +17 more locations

COMPLETEDNA271 miles

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

NCT01828593

The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g twice a day (BID) and SBI 5.0 g versus placebo on supporting nutrient absorption in HIV+ subjects with HIV-associated enteropathy.

HIV-associated Enteropathy

Entera Health, Inc103 participantsStarted Apr 2013

Los Angeles, California, United States • Sacramento, California, United States • San Francisco, California, United States +7 more locations

COMPLETEDPhase 2332 miles

Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)

NCT01260831

The purpose of this study is to evaluate the impact of Bedside Paediatric Early Warning System (Bedside-PEWS) on early identification of children at risk for near and actual cardiopulmonary arrest, hospital mortality, processes of care and PICU resource utilization.

Critically Ill Children

The Hospital for Sick Children144,539 participantsStarted Jan 2011

Brussels, Belgium • Calgary, Alberta, Canada • Edmonton, Alberta, Canada +19 more locations

PreviousPage 774 of 1046Next

Diabetes

in Philadelphia

Heart Diseasein Philadelphia